SEQUENT SCIENTIFIC share price has zoomed 5% and is presently trading at Rs 220.7.
Meanwhile, the BSE HEALTHCARE index is at 44,304.5 (up 0.9%).
Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 2.6%) and Dr. Reddys (up 2.2%).
SUVEN PHARMACEUTICALS (down 0.6%) and Jubilant Pharmova (down 0.6%) are among the top losers today.
Over the last one year, SEQUENT SCIENTIFIC has moved up from Rs 100.7 to Rs 220.7, registering a gain of Rs 120.0 (up 119.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 44,304.5, registering a gain of 57.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 207.8%), SUVEN PHARMACEUTICALS (up 132.2%) and Glenmark Pharma (up 129.9%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,060.2 (up 0.7%).
The top gainers among the BSE Sensex today are HCl Tech. (up 3.1%) and Infosys (up 3.1%). The most traded stocks in the BSE Sensex are ITC and Infosys.
In the meantime, NSE Nifty is at 24,401.2 (up 0.8%). Trent and HCl Tech. are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 80,060.2, registering a gain of 15,101.5 points (up 23.2%).
SEQUENT SCIENTIFIC net profit grew 126.1% YoY to Rs 91 million for the quarter ended June 2024, compared to a loss of Rs 347 million a year ago. Net sales rose 17.1% to Rs 3,902 million during the period as against Rs 3,332 million in April-June 2023.
For the year ended March 2024, SEQUENT SCIENTIFIC reported 75.7% increase in net profit to Rs -296 million compared to net loss of Rs 1,220 million during FY23. Revenue of the company fell 3.6% to Rs 13,697 million during FY24.
The current Price to earnings ratio of SEQUENT SCIENTIFIC, based on rolling 12 month earnings, stands at 390.2.
Equitymaster requests your view! Post a comment on "SEQUENT SCIENTIFIC Gains 5%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!